About Masimo Corporation
https://www.masimo.comMasimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
CEO
Catherine M. Szyman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:10.36M
Value:$1.43B
BLACKROCK INC.
Shares:9.35M
Value:$1.29B
FMR LLC
Shares:8.21M
Value:$1.14B
Summary
Showing Top 3 of 508
About Masimo Corporation
https://www.masimo.comMasimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $371.5M ▲ | $147M ▼ | $-100.4M ▼ | -27.03% ▼ | $-1.86 ▼ | $91.9M ▲ |
| Q2-2025 | $370.9M ▼ | $168.8M ▲ | $51.3M ▲ | 13.83% ▲ | $0.95 ▲ | $72M ▼ |
| Q1-2025 | $372M ▼ | $156M ▼ | $-170.7M ▲ | -45.89% ▲ | $-3.17 ▲ | $85.8M ▲ |
| Q4-2024 | $600.7M ▲ | $603.8M ▲ | $-349.6M ▼ | -58.2% ▼ | $-6.52 ▼ | $-320.9M ▼ |
| Q3-2024 | $504.6M | $233.1M | $9.8M | 1.94% | $0.18 | $73.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $314.7M ▲ | $1.82B ▼ | $1.01B ▼ | $810M ▼ |
| Q2-2025 | $149.6M ▲ | $2.4B ▲ | $1.36B ▲ | $1.04B ▲ |
| Q1-2025 | $130.8M ▼ | $2.29B ▼ | $1.35B ▼ | $946.4M ▼ |
| Q4-2024 | $177.6M ▲ | $2.63B ▼ | $1.57B ▼ | $1.05B ▼ |
| Q3-2024 | $158.5M | $3.09B | $1.62B | $1.46B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $53.7M ▲ | $56.8M ▼ | $282.3M ▲ | $-218.4M ▼ | $162.4M ▲ | $50.9M ▼ |
| Q2-2025 | $44.9M ▼ | $69.4M ▲ | $-9.2M ▼ | $-39.9M ▲ | $20.6M ▲ | $64.5M ▲ |
| Q1-2025 | $47.2M ▲ | $31.1M ▼ | $10.7M ▲ | $-47.8M ▼ | $-4.9M ▼ | $27M ▼ |
| Q4-2024 | $-349.6M ▼ | $50.5M ▲ | $-16.5M ▼ | $-6.5M ▼ | $17.7M ▼ | $47.5M ▲ |
| Q3-2024 | $-12.2M | $25.6M | $-13.5M | $-1.6M | $28.1M | $-4.7M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Health Care Segment | $710.00M ▲ | $370.00M ▼ | $370.00M ▲ | $370.00M ▲ |
Revenue by Geography
| Region | Q3-2021 | Q2-2021 | Q4-2021 | Q1-2022 |
|---|---|---|---|---|
 Americas | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Asia Pacific | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 EMEA | $60.00M ▲ | $60.00M ▲ | $70.00M ▲ | $60.00M ▼ |
 UNITED STATES | $210.00M ▲ | $200.00M ▼ | $210.00M ▲ | $200.00M ▼ |
CEO
Catherine M. Szyman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:10.36M
Value:$1.43B
BLACKROCK INC.
Shares:9.35M
Value:$1.29B
FMR LLC
Shares:8.21M
Value:$1.14B
Summary
Showing Top 3 of 508